← Back to All Filings

Akero Therapeutics CEO Gifts 14,739 Shares to Charity

Low SignificanceNovember 13, 2025 at 8:32:27 PM EST

Akero Therapeutics, Inc.

$AKRO4CIK: 0001744659

Subscribe to track AKRO

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Akero CEO Makes Charitable Stock Gift

Company: Akero Therapeutics, Inc. (AKRO) Form: 4 | Filed: 2025/11/13 Significance: Low

Insider: Cheng Andrew Title: President and CEO | Relationship: Director, Officer

Transaction: • Type: Gift • Shares: 14,739 • Price: $0.00 • Value: $0 • Owned After: 511,375

Key Insight: The President and CEO made a charitable donation of stock, a non-market transaction with minimal impact on share ownership or market sentiment.

Market Context: This is a routine disclosure of a gift and does not reflect a change in the insider's view of the company's prospects.

Comprehensive Analysis

SEC Filing Analysis: Akero Therapeutics, Inc. (AKRO)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: The President and CEO of Akero Therapeutics, Andrew Cheng, made a charitable gift of 14,739 shares of common stock.
  • Market Impact: Neutral. This is a non-market transaction and does not signal a change in insider sentiment.

Company Information

FieldValue
CompanyAkero Therapeutics, Inc.
Ticker SymbolAKRO
CIK0001744659
IndustryPHARMACEUTICAL PREPARATIONS

Insider Information

FieldValue
NameCheng Andrew
CIK0001778307
Title/PositionPresident and CEO
RelationshipDirector, Officer

Transaction Details

FieldValue
Form Type4
Transaction Date2025-11-12
Transaction CodeG (Gift)
Security TypeCommon Stock
Shares Involved14,739
Price Per Share$0.00
Total Value$0
Shares Owned After511,375
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$0
% of Market Cap0.00%
Shares Transacted14,739
% of Shares Outstanding0.018%
Post-Transaction Ownership511,375 shares (0.64% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: With a market capitalization of $4.47 billion, this $0 value transaction is financially immaterial.
  • Ownership Concentration: The CEO's ownership stake decreased slightly to 0.64% of total shares outstanding, which is a modest holding.
  • Transaction Significance: The transaction is a charitable gift, as confirmed by a footnote, and not an open-market sale. It holds no trading significance as it does not reflect market sentiment.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: A charitable gift is a personal financial decision and is not indicative of the insider's confidence in the company's future performance.

Volume & Sentiment

  • Expected Volume Impact: None. The transaction occurred off-market.
  • Sentiment Indicator: Neutral. The filing is informational and does not carry a bullish or bearish signal.

Additional Context

Special Circumstances

  • A footnote in the filing clarifies: "The reported transaction represents a bona fide charitable gift to a 501(c)(3) organization."
Topics:#SECFiling#InsiderTrading#AKRO#AkeroTherapeutics#Form4#CharitableGift#StockMarket#Investing

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.